EPISODE · Apr 27, 2026 · 1 MIN
Can Carboplatin Be Safely Omitted in Neoadjuvant HER2-Positive Breast Cancer? Evidence, Patient Selection, and Practice Impact
from TheBrief.Health · host TheBrief.Health
Reconsidering carboplatin in neoadjuvant HER2-positive breast cancer may reduce toxicity and resource use while maintaining outcomes, emphasizing individualized treatment decisions, patient experience, and careful monitoring.
What this episode covers
Reconsidering carboplatin in neoadjuvant HER2-positive breast cancer may reduce toxicity and resource use while maintaining outcomes, emphasizing individualized treatment decisions, patient experience, and careful monitoring.
NOW PLAYING
Can Carboplatin Be Safely Omitted in Neoadjuvant HER2-Positive Breast Cancer? Evidence, Patient Selection, and Practice Impact
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m